enzalutamide

You have access
End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
MINH DUNG NGUYEN, OLENA GOROBETS, YANNICK JOEL DJOUA, JOHAN ROSE-DITE-MODESTINE, VINCENT VINH-HUNG, CLAIRE VERSCHRAEGEN and NAM P. NGUYEN

Anticancer Research June 2025, 45 (6) 2535-2538; DOI: https://doi.org/10.21873/anticanres.17625
You have access
Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases
NAOTO WAKITA, TAKUTO HARA, KOTARO SUZUKI, TOMOAKI TERAKAWA, JUN TEISHIMA, YUZO NAKANO and HIDEAKI MIYAKE

Anticancer Research June 2024, 44 (6) 2627-2635; DOI: https://doi.org/10.21873/anticanres.17069
Open Access
Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer
YUJIRO NAGATA, KAZUMASA JOJIMA, TAKUO MATSUKAWA, IKKO TOMISAKI and NAOHIRO FUJIMOTO

Anticancer Research October 2023, 43 (10) 4573-4581; DOI: https://doi.org/10.21873/anticanres.16651
Open Access
Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer
YUJIRO NAGATA, TAKUO MATSUKAWA, IKKO TOMISAKI and NAOHIRO FUJIMOTO

Anticancer Research January 2023, 43 (1) 429-436; DOI: https://doi.org/10.21873/anticanres.16178
You have access
Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience
ONDREJ FIALA, PETR HOSEK, HANA KORUNKOVA, MILAN HORA, JIRI KOLAR, JINDRA WINDRICHOVA, ONDREJ SOREJS, ONDREJ TOPOLCAN, IVAN TRAVNICEK, HANA SEDLACKOVA and JINDRICH FINEK

Anticancer Research January 2023, 43 (1) 463-471; DOI: https://doi.org/10.21873/anticanres.16183
You have access
Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, CHUAN-SHU CHEN, CHENG-KUANG YANG, KEVIN LU, CHEN-LI CHENG, SHENG-CHUN HUNG, SHU-YEN CHEN, CHIANN YI HSU and KUN-YUAN CHIU

Anticancer Research October 2022, 42 (10) 4857-4866; DOI: https://doi.org/10.21873/anticanres.15991
Open Access
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease
NAOHIRO FUJIMOTO, AKINORI MINATO, TSUKASA IGAWA, TASUKU HIROSHIGE, WATARU OBARA, ATSUSHI FUKUDA, YUJIRO NAGATA, YUI MIZUSHIMA, IKKO TOMISAKI and KENICHI HARADA

Anticancer Research June 2022, 42 (6) 3041-3047; DOI: https://doi.org/10.21873/anticanres.15790
You have access
Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy
MOTOHIRO FUJIWARA, RYO FUJIWARA, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA

Anticancer Research April 2022, 42 (4) 2123-2130; DOI: https://doi.org/10.21873/anticanres.15694
You have access
Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer
AKIYO HORI, HARUKA SAHASHI, SORA SANO, EMIRI MATSUMIYA, MAHO ARIGA, AKARI ASANO, MIDORI SODA, CHITOSHI GOTO, TAKASHI MIZUI, HISAO KOMEDA and KIYOYUKI KITAICHI

Anticancer Research December 2020, 40 (12) 7101-7108; DOI: https://doi.org/10.21873/anticanres.14739
You have access
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO

Anticancer Research January 2020, 40 (1) 335-339; DOI: https://doi.org/10.21873/anticanres.13957

Main menu

User menu

Search

enzalutamide

Pages